Article Text
Statistics from Altmetric.com
Distinguishing duct dependent congenital heart disease (DDCHD) from other causes of hypoxaemia, notably persistent pulmonary hypertension (PPHN), represents a diagnostic and therapeutic dilemma for neonatal transport teams, specifically in relation to use of prostaglandin E1 (PGE1). In non-DDCHD, PGE1 is considered unnecessary and likely to produce unwanted side-effects including apnoea and hypotension.1
We report our observations of the effects of PGE1 infusion in a group of babies with evidence of PPHN but without DDCHD.
We reviewed the data on all infants ≤10 days and ≥34 weeks gestation with suspected DDCHD and/or PPHN transferred by the Newborn Emergency Transport Service (NETS), Victoria, from non-tertiary neonatal units to the regional paediatric cardiac …
Footnotes
-
Contributors All authors were responsible for planning and reporting. NG and NP conducted the data collection and analysis.
-
Funding None.
-
Competing interests None.
-
Ethics approval Royal Children's Hospital, Melbourne, Australia.
-
Provenance and peer review Not commissioned; externally peer reviewed.